Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

LEUVEN, Belgium, September 11 /PRNewswire-FirstCall/ --

- ThromboGenics' Significant Achievements Over the Last Year are Recognised in Nominations

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the "Biotech Company of the Year" and "Licensing Deal of the Year" awards at the Scrip Awards 2009. These nominations recognise the transformational year that ThromboGenics has had, and the progress it has made toward becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines.

The Biotech Company of the Year award recognises the progress and achievement a biotech company has made within the last twelve months. During the period, ThromboGenics has started the pivotal transatlantic Phase III programme with microplasmin for back of the eye disease, signed a EUR500 million partnership deal with Roche for its novel anti-cancer antibody TB-403, and moved its novel anti-coagulant TB-402 into Phase II trials. TB-402 is another potential partnership opportunity. There are four other companies nominated in this category.

The Licensing Deal of the Year award acknowledges the achievement of a Company in signing a licensing deal that has both monetary and strategic benefits to all parties. ThromboGenics signed a major partnership deal with Roche for TB-403 under which the Company and co-development partner BioInvent received an upfront payment of EUR50 million, an additional EUR450 million in potential milestones, and double digit royalties on future product sales. There are four other licensing deals nominated in this category.

The Scrip Awards is one of the biotechnology and pharmaceutical industry's most prestigious and highly contested awards event. The event is in its fif
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014   Sequenom, Inc. (NASDAQ: ... provides innovative genetic analysis solutions, and Mayo Medical ... services in the United States , ... patents and applications. "We have great appreciation ... care, and we welcome the opportunity to partner with ...
(Date:7/29/2014)... Human Longevity, Inc. (HLI), a genomics and ... the healthy, high performance human life span, today announced ... expert in machine learning and machine translation as the ... Google where he was Distinguished Research Scientist and the ... HLI Co-Founder and CEO, J. Craig Venter , ...
(Date:7/29/2014)... particle be separated from its properties? On July 29, ... results of the first Cheshire Cat experiment, separating a ... in Orange, CA, and Vienna University of Technology. , ... grin," thought Alice in Wonderland, "but a grin without ... saw in my life!" Alice,s surprise stems from her ...
(Date:7/29/2014)... 2014) Tough, ultralight foam of atom-thick sheets can ... chemical process invented at Rice University. , In ... nanoscale building, with floors and walls that reinforce each ... materials: floors and walls of graphene oxide that self-assemble ... , The researchers say the foam could find use ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4Tough foam from tiny sheets 2
... , , COLUMBIA, Md., Dec. 16 Martek ... for the fourth quarter and fiscal year ended October 31, 2009. ... $90.4 million in the fourth quarter of fiscal 2008. Net income ... quarter of fiscal 2009, a 5% increase compared with $10.5 million, ...
... , , LAS VEGAS, Dec. 16 Cord Blood America, Inc. ... company ( http://www.cordblood-america.com ) focused on bringing the life saving ... and internationally, said today that it has reduced its debt by ... of 2009 and total debt eliminated for the year now tops ...
... , , ... Inc. (Nasdaq: SQNM ), today announced the appointment of Dr. ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) , Kenneth F. Buechler, ... From 1988 to 1994, Dr. Buechler was Biosite,s director of chemistry. ...
Cached Biology Technology:Martek Announces Fourth Quarter and FY 2009 Financial Results 2Martek Announces Fourth Quarter and FY 2009 Financial Results 3Martek Announces Fourth Quarter and FY 2009 Financial Results 4Martek Announces Fourth Quarter and FY 2009 Financial Results 5Martek Announces Fourth Quarter and FY 2009 Financial Results 6Martek Announces Fourth Quarter and FY 2009 Financial Results 7Martek Announces Fourth Quarter and FY 2009 Financial Results 8Martek Announces Fourth Quarter and FY 2009 Financial Results 9Martek Announces Fourth Quarter and FY 2009 Financial Results 10Martek Announces Fourth Quarter and FY 2009 Financial Results 11Martek Announces Fourth Quarter and FY 2009 Financial Results 12Martek Announces Fourth Quarter and FY 2009 Financial Results 13Martek Announces Fourth Quarter and FY 2009 Financial Results 14Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3
(Date:7/29/2014)... fascinating journey to the edge of science, Clment Vidal ... The Beginning and the End: Does our universe have ... Are we alone in the universe? What is the ... Grounded in science and committed to philosophical rigor, the ... intelligent life is not an accident, but may well ...
(Date:7/29/2014)... comes to technology, healthcare is usually one of the last industries ... comes to wearables, healthcare is trying to move ahead of the ... and its wearable cousins is less than mature, these devices are ... in the hospital for a major procedure or for personal use ... mind, InformationWeek editor Rodney Brown set out to ...
(Date:7/29/2014)... personal genetics company, has received from the National ... for a two-year project to support the further ... for genetic discovery. , Specifically, the grant ... of web-based surveys to improve the company,s ability ... of survey tools to support the collection of ...
Breaking Biology News(10 mins):Book: 'The Beginning and the End' 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3
... found that the number of pests and disease outbreaks in ... The review "The consequences of Tree Pests and ... Southampton, Cambridge, Oxford and St Andrews is published today (15 ... shows that the experience of widespread death of trees, similar ...
... Clinic Lerner Research Institute have discovered recent genetic mutations ... of malaria annuallychanges that may render tens of millions ... infection. Peter A. Zimmerman, professor of international health, ... of Medicine, and David Serre, a scientific staff member ...
... , Nov. 14, 2013 Wake Forest Baptist Medical ... first-of-its-kind strategic affiliation agreement in the Triad with Cornerstone ... Cornerstone Health Enablement Strategic Solutions, LLC (CHESS). ... both partners for new models of health care delivery ...
Cached Biology News:Rising concerns over tree pests and diseases 2Vivax malaria may be evolving around natural defense 2Vivax malaria may be evolving around natural defense 3Wake Forest Baptist Medical Center and Cornerstone Health Care Join in Unique Affiliation 2Wake Forest Baptist Medical Center and Cornerstone Health Care Join in Unique Affiliation 3
... The Bio-Plex suspension array system, 100-240 V, ... for simultaneous quantitative analysis of up to ... microplate well. The suspension array is composed ... each of which may be conjugated with ...
...
... Disposable. Virgin, optically clear polystyrene with ... alphanumeric coordinates for cell counting. 100% ... is a new product number, created ... If showing no availability yet, please ...
... 100 IS System is a compact analysis system ... lasers, optics, fluidics, a controller, advanced digital signal ... compact lab analysis system includes the Luminex 100, ... has a DMF file at the FDA, and ...
Biology Products: